Survival of Medicare fee-for-service chemotherapy patients by site of care

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Pamela M. Pelizzari, Christine Ferro, Sean Pittinger, Bruce S. Pyenson | 07 February 2018

Few studies compare cancer survival outcomes across mutlple cancer treatment facility types simultaneously. This report compares the 36-month cancer survival rate by treatment facility type for 46,762 Medicare fee-for-service patients treated with chemotherapy under the Medicare Part B benefit for breast, colon, lung, ovarian, pancreatic, or prostate cancer. It compares prospective payment system-exempt cancer hospitals to National Cancer Institute-designated cancer centers, teaching hospitals, and all other hospitals.

This report was commissioned by the Alliance of Dedicated Cancer Centers.